Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses

David M. Hone, Shaoguang Wu, Robert J. Powell, David W. Pascual, John Van Cott, Jerry McGhee, Timothy R. Fouts, Robert G. Tuskan, George K. Lewis

Research output: Contribution to journalArticle

Abstract

Recent evidence suggests that live oral Salmonella-HIV vaccine vectors have the potential to elicit HIV-specific T cell-mediated immunity in both the mucosal and systemic compartments. We are using the mouse-typhoid model to identify Salmonella::HIV vaccine vector constructs that elicit HIV-specific mucosal and systemic immune responses. Oral immunization of mice with a Salmonella strain that expresses recombinant gpl20 (rgp120) in the cytoplasm of the vector elicits a modest gp120-specific T cell proliferation response in the spleen. However, such Salmonella constructs did not stimulate the development of gp120-specific serum IgG or cytotoxic T lymphocytes (CTLs). Interestingly, the majority of cytoplasmically-expressed rgp120 forms inclusion bodies in Salmonella. We believe that in this form rgp120 is highly susceptible to protease degradation by the vector. As such, cytoplasmic rgp120 may not persist in the host after vaccination, resulting in the modest immunogenicity of rgp120 in these constructs. To circumvent this problem we constructed Salmonella strains that express rgp120 on the surface of the vector. Preliminary data suggest that surface-expressed rgp120 is significantly more immunogenic in both the mucosal and systemic compartments than cytoplasmic rgp120. These results, therefore, support the proposal that Salmonella vectors will be a safe and inexpensive means for delivery of HIV antigens to, and the elicitation of HIV-specific T cells in, the mucosal and systemic compartments.

Original languageEnglish (US)
Pages (from-to)203-207
Number of pages5
JournalJournal of Biotechnology
Volume44
Issue number1-3
DOIs
StatePublished - Jan 26 1996
Externally publishedYes

Fingerprint

AIDS Vaccines
Mucosal Immunity
Salmonella
Vaccines
HIV-1
HIV
T-cells
Salmonella Vaccines
T-Lymphocytes
HIV Antigens
Typhoid Fever
Inclusion Bodies
Cytotoxic T-Lymphocytes
Cellular Immunity
Immunization
Cytoplasm
Vaccination
Peptide Hydrolases
Spleen
Cell proliferation

Keywords

  • Gp120
  • HIV-1
  • Mucosal immunity
  • Salmonella
  • Vaccine vector

ASJC Scopus subject areas

  • Biotechnology

Cite this

Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses. / Hone, David M.; Wu, Shaoguang; Powell, Robert J.; Pascual, David W.; Van Cott, John; McGhee, Jerry; Fouts, Timothy R.; Tuskan, Robert G.; Lewis, George K.

In: Journal of Biotechnology, Vol. 44, No. 1-3, 26.01.1996, p. 203-207.

Research output: Contribution to journalArticle

Hone, David M. ; Wu, Shaoguang ; Powell, Robert J. ; Pascual, David W. ; Van Cott, John ; McGhee, Jerry ; Fouts, Timothy R. ; Tuskan, Robert G. ; Lewis, George K. / Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses. In: Journal of Biotechnology. 1996 ; Vol. 44, No. 1-3. pp. 203-207.
@article{565254f842904551b5ed53b6a210355b,
title = "Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses",
abstract = "Recent evidence suggests that live oral Salmonella-HIV vaccine vectors have the potential to elicit HIV-specific T cell-mediated immunity in both the mucosal and systemic compartments. We are using the mouse-typhoid model to identify Salmonella::HIV vaccine vector constructs that elicit HIV-specific mucosal and systemic immune responses. Oral immunization of mice with a Salmonella strain that expresses recombinant gpl20 (rgp120) in the cytoplasm of the vector elicits a modest gp120-specific T cell proliferation response in the spleen. However, such Salmonella constructs did not stimulate the development of gp120-specific serum IgG or cytotoxic T lymphocytes (CTLs). Interestingly, the majority of cytoplasmically-expressed rgp120 forms inclusion bodies in Salmonella. We believe that in this form rgp120 is highly susceptible to protease degradation by the vector. As such, cytoplasmic rgp120 may not persist in the host after vaccination, resulting in the modest immunogenicity of rgp120 in these constructs. To circumvent this problem we constructed Salmonella strains that express rgp120 on the surface of the vector. Preliminary data suggest that surface-expressed rgp120 is significantly more immunogenic in both the mucosal and systemic compartments than cytoplasmic rgp120. These results, therefore, support the proposal that Salmonella vectors will be a safe and inexpensive means for delivery of HIV antigens to, and the elicitation of HIV-specific T cells in, the mucosal and systemic compartments.",
keywords = "Gp120, HIV-1, Mucosal immunity, Salmonella, Vaccine vector",
author = "Hone, {David M.} and Shaoguang Wu and Powell, {Robert J.} and Pascual, {David W.} and {Van Cott}, John and Jerry McGhee and Fouts, {Timothy R.} and Tuskan, {Robert G.} and Lewis, {George K.}",
year = "1996",
month = "1",
day = "26",
doi = "10.1016/0168-1656(95)00151-4",
language = "English (US)",
volume = "44",
pages = "203--207",
journal = "Journal of Biotechnology",
issn = "0168-1656",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses

AU - Hone, David M.

AU - Wu, Shaoguang

AU - Powell, Robert J.

AU - Pascual, David W.

AU - Van Cott, John

AU - McGhee, Jerry

AU - Fouts, Timothy R.

AU - Tuskan, Robert G.

AU - Lewis, George K.

PY - 1996/1/26

Y1 - 1996/1/26

N2 - Recent evidence suggests that live oral Salmonella-HIV vaccine vectors have the potential to elicit HIV-specific T cell-mediated immunity in both the mucosal and systemic compartments. We are using the mouse-typhoid model to identify Salmonella::HIV vaccine vector constructs that elicit HIV-specific mucosal and systemic immune responses. Oral immunization of mice with a Salmonella strain that expresses recombinant gpl20 (rgp120) in the cytoplasm of the vector elicits a modest gp120-specific T cell proliferation response in the spleen. However, such Salmonella constructs did not stimulate the development of gp120-specific serum IgG or cytotoxic T lymphocytes (CTLs). Interestingly, the majority of cytoplasmically-expressed rgp120 forms inclusion bodies in Salmonella. We believe that in this form rgp120 is highly susceptible to protease degradation by the vector. As such, cytoplasmic rgp120 may not persist in the host after vaccination, resulting in the modest immunogenicity of rgp120 in these constructs. To circumvent this problem we constructed Salmonella strains that express rgp120 on the surface of the vector. Preliminary data suggest that surface-expressed rgp120 is significantly more immunogenic in both the mucosal and systemic compartments than cytoplasmic rgp120. These results, therefore, support the proposal that Salmonella vectors will be a safe and inexpensive means for delivery of HIV antigens to, and the elicitation of HIV-specific T cells in, the mucosal and systemic compartments.

AB - Recent evidence suggests that live oral Salmonella-HIV vaccine vectors have the potential to elicit HIV-specific T cell-mediated immunity in both the mucosal and systemic compartments. We are using the mouse-typhoid model to identify Salmonella::HIV vaccine vector constructs that elicit HIV-specific mucosal and systemic immune responses. Oral immunization of mice with a Salmonella strain that expresses recombinant gpl20 (rgp120) in the cytoplasm of the vector elicits a modest gp120-specific T cell proliferation response in the spleen. However, such Salmonella constructs did not stimulate the development of gp120-specific serum IgG or cytotoxic T lymphocytes (CTLs). Interestingly, the majority of cytoplasmically-expressed rgp120 forms inclusion bodies in Salmonella. We believe that in this form rgp120 is highly susceptible to protease degradation by the vector. As such, cytoplasmic rgp120 may not persist in the host after vaccination, resulting in the modest immunogenicity of rgp120 in these constructs. To circumvent this problem we constructed Salmonella strains that express rgp120 on the surface of the vector. Preliminary data suggest that surface-expressed rgp120 is significantly more immunogenic in both the mucosal and systemic compartments than cytoplasmic rgp120. These results, therefore, support the proposal that Salmonella vectors will be a safe and inexpensive means for delivery of HIV antigens to, and the elicitation of HIV-specific T cells in, the mucosal and systemic compartments.

KW - Gp120

KW - HIV-1

KW - Mucosal immunity

KW - Salmonella

KW - Vaccine vector

UR - http://www.scopus.com/inward/record.url?scp=0030047688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030047688&partnerID=8YFLogxK

U2 - 10.1016/0168-1656(95)00151-4

DO - 10.1016/0168-1656(95)00151-4

M3 - Article

C2 - 8717405

AN - SCOPUS:0030047688

VL - 44

SP - 203

EP - 207

JO - Journal of Biotechnology

JF - Journal of Biotechnology

SN - 0168-1656

IS - 1-3

ER -